121 related articles for article (PubMed ID: 15223636)
1. Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia.
Ito S; Ishida Y; Oyake T; Satoh M; Aoki Y; Kowata S; Uchiyama T; Enomoto S; Sugawara T; Numaoka H; Suzuki K; Murai K
Leuk Lymphoma; 2004 Sep; 45(9):1783-9. PubMed ID: 15223636
[TBL] [Abstract][Full Text] [Related]
2. Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts.
Ono T; Takeshita A; Kishimoto Y; Kiyoi H; Okada M; Yamauchi T; Emi N; Horikawa K; Matsuda M; Shinagawa K; Monma F; Ohtake S; Nakaseko C; Takahashi M; Kimura Y; Iwanaga M; Asou N; Naoe T;
Cancer Sci; 2014 Jan; 105(1):97-104. PubMed ID: 24206578
[TBL] [Abstract][Full Text] [Related]
3. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy.
Ferrara F; Morabito F; Martino B; Specchia G; Liso V; Nobile F; Boccuni P; Di Noto R; Pane F; Annunziata M; Schiavone EM; De Simone M; Guglielmi C; Del Vecchio L; Lo Coco F
J Clin Oncol; 2000 Mar; 18(6):1295-300. PubMed ID: 10715300
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.
Montesinos P; Rayón C; Vellenga E; Brunet S; González J; González M; Holowiecka A; Esteve J; Bergua J; González JD; Rivas C; Tormo M; Rubio V; Bueno J; Manso F; Milone G; de la Serna J; Pérez I; Pérez-Encinas M; Krsnik I; Ribera JM; Escoda L; Lowenberg B; Sanz MA; ;
Blood; 2011 Feb; 117(6):1799-805. PubMed ID: 21148082
[TBL] [Abstract][Full Text] [Related]
5. An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens.
Sobas M; Montesinos P; Boluda B; Bernal T; Vellenga E; Nomdedeu J; González-Campos J; Chillón M; Holowiecka A; Esteve J; Bergua J; González-Sanmiguel JD; Gil-Cortes C; Tormo M; Salamero O; Manso F; Fernández I; de la Serna J; Moreno MJ; Pérez-Encinas M; Krsnik I; Ribera JM; Escoda L; Lowenberg B; Sanz MA;
Leuk Lymphoma; 2019 Apr; 60(4):1030-1035. PubMed ID: 30322324
[TBL] [Abstract][Full Text] [Related]
6. CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome?
Murray CK; Estey E; Paietta E; Howard RS; Edenfield WJ; Pierce S; Mann KP; Bolan C; Byrd JC
J Clin Oncol; 1999 Jan; 17(1):293-7. PubMed ID: 10458245
[TBL] [Abstract][Full Text] [Related]
7. All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan.
Ohno R; Ohnishi K; Takeshita A; Tanimoto M; Murakami H; Kanamaru A; Asou N; Kobayashi T; Kuriyama K; Ohmoto E
Leukemia; 1994; 8 Suppl 3():S64-9. PubMed ID: 7808028
[TBL] [Abstract][Full Text] [Related]
8. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of CD56 antigen expression in acute myeloid leukemia.
Di Bona E; Sartori R; Zambello R; Guercini N; Madeo D; Rodeghiero F
Haematologica; 2002 Mar; 87(3):250-6. PubMed ID: 11869936
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
Testa U; Lo-Coco F
Ann Hematol; 2016 Apr; 95(5):673-80. PubMed ID: 26920716
[TBL] [Abstract][Full Text] [Related]
11. The biological characteristics of CD34+ CD2+ adult acute promyelocytic leukemia and the CD34 CD2 hypergranular (M3) and microgranular (M3v) phenotypes.
Albano F; Mestice A; Pannunzio A; Lanza F; Martino B; Pastore D; Ferrara F; Carluccio P; Nobile F; Castoldi G; Liso V; Specchia G
Haematologica; 2006 Mar; 91(3):311-6. PubMed ID: 16531253
[TBL] [Abstract][Full Text] [Related]
12. [Clinical and laboratory features of patients with CD34(+) acute promyelocytic leukemia].
Liang JY; Wu DP; Liu YJ; Ma QF; Xue YQ; Zhu MQ; Chen ZX
Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):196-8. PubMed ID: 19615259
[TBL] [Abstract][Full Text] [Related]
13. Minimal Coexpression of CD34+/CD56+ in Acute Promyelocytic Leukemia Is Associated With Relapse.
Maenhout TM; Moreau E; Van Haute I; Desmet S; Deeren D
Am J Clin Pathol; 2015 Aug; 144(2):347-51. PubMed ID: 26185322
[TBL] [Abstract][Full Text] [Related]
14. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
[TBL] [Abstract][Full Text] [Related]
15. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience.
Kelaidi C; Chevret S; De Botton S; Raffoux E; Guerci A; Thomas X; Pigneux A; Lamy T; Rigal-Huguet F; Meyer-Monard S; Chevallier P; Maloisel F; Deconinck E; Ferrant A; Fegueux N; Ifrah N; Sanz M; Dombret H; Fenaux P; Adès L
J Clin Oncol; 2009 Jun; 27(16):2668-76. PubMed ID: 19414681
[TBL] [Abstract][Full Text] [Related]
16. Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series.
Tsimberidou AM; Tirado-Gomez M; Andreeff M; O'Brien S; Kantarjian H; Keating M; Lopez-Berestein G; Estey E
Leuk Lymphoma; 2006 Jun; 47(6):1062-8. PubMed ID: 16840198
[TBL] [Abstract][Full Text] [Related]
17. HLA-DRneg patients without acute promyelocytic leukemia show distinct immunophenotypic, genetic, molecular, and cytomorphologic characteristics compared to acute promyelocytic leukemia.
Oelschlaegel U; Mohr B; Schaich M; Schäkel U; Kroschinsky F; Illmer T; Ehninger G; Thiede C
Cytometry B Clin Cytom; 2009 Sep; 76(5):321-7. PubMed ID: 19291801
[TBL] [Abstract][Full Text] [Related]
18. Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines.
Lengfelder E; Görlich D; Nowak D; Spiekermann K; Haferlach C; Krug U; Kreuzer KA; Braess J; Schliemann C; Lindemann HW; Horst HA; Schiel X; Flasshove M; Hecht A; Schnittger S; Schneider S; Wörmann B; Hofmann WK; Berdel WE; Bormann E; Sauerland C; Büchner T; Hiddemann W;
Eur J Haematol; 2018 Feb; 100(2):154-162. PubMed ID: 29114972
[TBL] [Abstract][Full Text] [Related]
19. CNS relapses of acute promyelocytic leukemia after all-trans retinoic acid.
Burry LD; Seki JT
Ann Pharmacother; 2002 Dec; 36(12):1900-6. PubMed ID: 12452754
[TBL] [Abstract][Full Text] [Related]
20. C-fms expression correlates with monocytic differentiation in PML-RAR alpha+ acute promyelocytic leukemia.
Riccioni R; Saulle E; Militi S; Sposi NM; Gualtiero M; Mauro N; Mancini M; Diverio D; Lo Coco F; Peschle C; Testa U
Leukemia; 2003 Jan; 17(1):98-113. PubMed ID: 12529666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
